Compare TPB & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPB | GENB |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2015 | N/A |
| Metric | TPB | GENB |
|---|---|---|
| Price | $87.74 | $14.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $115.00 | $23.20 |
| AVG Volume (30 Days) | 465.9K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 45.33 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $463,062,000.00 | N/A |
| Revenue This Year | $13.68 | N/A |
| Revenue Next Year | $11.32 | $16.58 |
| P/E Ratio | $28.31 | ★ N/A |
| Revenue Growth | ★ 28.39 | N/A |
| 52 Week Low | $65.80 | $11.00 |
| 52 Week High | $146.90 | $18.18 |
| Indicator | TPB | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 45.42 |
| Support Level | $83.96 | $11.73 |
| Resistance Level | $93.44 | $15.05 |
| Average True Range (ATR) | 4.28 | 1.25 |
| MACD | 0.61 | -0.17 |
| Stochastic Oscillator | 83.69 | 13.29 |
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.